Charles River Laboratories International, Inc. Stock News

Charles River (CRL) Q2 EPS Jumps 11%

Charles River Laboratories International, Inc. (NYSE:CRL ) Q2 2025 Earnings Conference Call August 6, 2025 9:00 AM ET Company Participants Flavia H. Pease - Corporate Executive VP & CFO James C.

Charles River Laboratories posted a strong Q2 beat, but results were boosted by one-time items and cost cuts that may not be sustainable. Ongoing risks include regulatory pressure to phase out animal testing and weak organic revenue growth, especially in the Discovery and Safety Assessment segment. Management raised full-year guidance, but H2 faces margin and revenue headwinds; Q3 EPS is expect...

Charles River Laboratories on Wednesday raised its annual profit forecast, betting on growing demand for its drug discovery and development services from drugmakers, sending its shares up more than 4% in premarket trading.

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Second-Quarter 2025 Results.

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--As part of Charles River's Cell & Gene Therapy Accelerator Program, Elly's Team manufactured critical starting materials for a Phase I clinical trial.

Shares in Creightons PLC (LSE:CRL) dropped 10% on Wednesday despite reporting a return to profitability, as investors reacted to a cautious outlook for the year ahead. The beauty and personal care manufacturer posted a 1.6% rise in revenue to £54.1 million for the year to 31 March 2025, with strong growth in private label sales offsetting declines in branded and contract manufacturing.

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call.